Table 1 Baseline patient characteristics in the EGFR 19 and 21 mutation groups
N | 19 del (n = 184) | 21 L858R (n = 179) | P | |
|---|---|---|---|---|
Age (mean ± SD) | 363 | 58.69 ± 10.19 | 60.87 ± 10.33 | 0.044 |
Gender, n (%) | ||||
Male | 137 | 75 (40.76) | 62 (34.64) | 0.229 |
Female | 226 | 109 (59.24) | 117 (65.36) | |
Smoking, n (%) | ||||
Yes | 83 | 47 (25.54) | 36 (20.11) | 0.218 |
No | 280 | 137 (74.46) | 143 (79.89) | |
Family history, n (%) | ||||
Yes | 62 | 27 (14.67) | 35 (19.55) | 0.174 |
No | 301 | 157 (85.79) | 144 (80.45) | |
Type, n (%) | ||||
AD | 347 | 175 (95.11) | 172 (96.09) | 0.649 |
Other | 16 | 9 (4.89) | 7 (3.91) | |
Differentiation, n (%) | ||||
High | 49 | 23 (12.85) | 26 (15.29) | 0.663 |
Middle | 246 | 130 (72.63) | 116 (68.24) | |
Low | 54 | 26 (14.53) | 28 (16.47) | |
Stage, n (%) | 0.026 | |||
I | 87 | 52 (28.26) | 35 (19.55) | |
II | 52 | 26 (14.13) | 26 (14.53) | |
III | 168 | 72 (39.13) | 96 (53.63) | |
IV | 56 | 34 (18.48) | 22 (12.29) | |
Operation, n (%) | 0.302 | |||
Radical | 288 | 142 (77.17) | 146 (81.56) | |
Palliative | 75 | 42 (22.83) | 33 (18.44) | |
Adjuvant chemotherapy | 0.157 | |||
Yes | 285 | 150 (81.52) | 135 (75.42) | |
No | 78 | 34 (18.48) | 44 (24.58) | |
Adjuvant radiation | 0.395 | |||
Yes | 111 | 60 (32.61) | 51 (28.49) | |
No | 252 | 124 (67.39) | 128 (71.51) | |
TKI | 0.886 | |||
Gefitinib | 237 | 123 (66.85) | 114 (63.69) | |
Erlotinib | 55 | 28 (15.22) | 27 (15.08) | |
Icotinib | 58 | 27 (14.67) | 31 (17.32) | |
Others | 13 | 6 (3.26) | 7 (3.91) | |